Parsley Health has launched a new program that focuses on providing comprehensive care for working women with complex and chronic health concerns. The program aims to deliver exceptional health outcomes by addressing a wide range of medical conditions, including autoimmune, gastrointestinal, cardiometabolic, behavioral health, and hormonal conditions. It covers women throughout their reproductive health to menopause and combines high-touch, tech-enabled virtual care…
Transdermal Diagnostics, a University of Bath spinout company developing technology to monitor glucose levels non-invasively, has received £800K in seed funding and a £300K grant from Innovate UK. The seed round was led by QUBIS, which specialises in innovation focused spin-out companies, and includes Pioneer Group, Immetric, Bristol Private Equity Club and Science Angel Syndicate. In March 2022, the researchers – led…
Virtual primary care company Alpha Medical is expanding its services to treat Prediabetes, Type 2 Diabetes, and Gestational Diabetes through affordable and flexible treatment plans. The new offering includes clinical care offerings to help treat and screen for Prediabetes, Type 2 Diabetes, and screen for Gestational Diabetes. With this new service, Alpha now offers a full-service approach to diabetes treatment, including the…
Fibromyalgia is a condition that causes widespread pain all over the body, sleep problems, fatigue, and often emotional and mental distress. People with fibromyalgia may be more sensitive to pain than people without fibromyalgia. The cause of fibromyalgia is not known, but it can be effectively treated and managed. In the U.S. around 4 million people are affected. Women are twice as…
PCOS startup Allara is adding some star power to the team and has announced that Jaime King, actor, filmmaker, and activist, now supports the company as both investor and Director of Impact. King, who struggled with infertility herself, is joining Allara on its mission to destigmatize PCOS. PCOS, short for Polycystic Ovary Syndrome, affects 1 in 10 women globally. Around 50% of women with…
Celmatix, a New York-based pre-clinical stage biotech company focused on ovarian biology, has announced today that a novel PCOS target identified as part of its five-year, multi-target alliance with Evotec, has progressed into hit-identification. It may still be early in the process, but what this milestone essentially means is that Celmatix, Evotec and pharma leader Bayer, who formed a “PCOS alliance” around…
